Physician

Kamal Sharma, D.O.

According to 2025 Medicare claims, Kamal Sharma, D.O. (NPI: 1093914988) practices medical oncology in the Lakeland-Winter Haven, FL market, with the plurality of this provider's patient population coming from Polk, FL. This provider's primary affiliated billing organization is THE ONCOLOGY INSTITUTE FL, LLC (NPI: 1730142373; TIN: 043589781) and primary practice location at 33812-3319.

Sharma's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 58 traditional Medicare patients, billed 14,626 HCPCS/CPT codes, and received $252,602 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 436 prescription claims across 96 beneficiaries totaling $726,245 in drug costs, led by Ondansetron Hcl (Ondansetron Hcl). 2023 DME data shows 22 claims. Open Payments data shows 121 records totaling $97,765. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $194,388 to $252,602. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $422,261 and ending at $726,245. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	157	8,640	$194,388
2016	195	315	$24,888
2017	235	650	$47,690
2018	300	903	$64,432
2019	293	1,033	$78,981
2020	272	911	$76,084
2021	272	884	$97,533
2022	11	4,011	$60,867
2023	42	8,158	$252,141
2024	58	14,626	$252,602

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	115	410	$422,261
2016	105	298	$393,871
2017	142	564	$320,679
2018	186	820	$622,489
2019	194	915	$1,040,657
2020	215	1,173	$1,197,101
2021	216	1,131	$1,864,598
2022	90	319	$612,628
2023	86	433	$554,831
2024	96	436	$726,245

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	77	$3,445
2016	N/R	N/R	N/R
2017	N/R	11	$989
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	23	$1,259
2022	N/R	N/R	N/R
2023	N/R	22	$1,193
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	37	121	$100
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	14	28	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	26	43	$14
36415	Insertion of needle into vein for collection of blood sample	19	48	$8
J1200	Injection, diphenhydramine hcl, up to 50 mg	14	62	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ondansetron Hcl	Ondansetron Hcl	30	584	$1,688
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	40	938	$1,675
Anastrozole	Anastrozole	22	1,488	$436
Lidocaine-Prilocaine	Lidocaine/Prilocaine	24	825	$364
Dexamethasone	Dexamethasone	19	660	$363

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	118	$3,049	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$94,716	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kamal Sharma, D.O.?

Tedicare shows public-source Medicare data for Kamal Sharma, D.O. (NPI 1093914988), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kamal Sharma, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Kamal Sharma, D.O.?

Kamal Sharma, D.O. is linked to THE ONCOLOGY INSTITUTE FL, LLC (billing NPI 1730142373) in the available physician profile data.

Does Kamal Sharma, D.O. have Open Payments data?

Kamal Sharma, D.O. has 121 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.